MA37647A1 - Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci - Google Patents

Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Info

Publication number
MA37647A1
MA37647A1 MA37647A MA37647A MA37647A1 MA 37647 A1 MA37647 A1 MA 37647A1 MA 37647 A MA37647 A MA 37647A MA 37647 A MA37647 A MA 37647A MA 37647 A1 MA37647 A1 MA 37647A1
Authority
MA
Morocco
Prior art keywords
salts
compounds
producing hydroxylated
cyclopentapyrimidine compounds
hydroxylated cyclopentapyrimidine
Prior art date
Application number
MA37647A
Other languages
English (en)
Inventor
Srinivasan Babu
Francis Gosselin
Yingqing Ran
Travis Remarchuk
Scott J Savage
Jeffrey Stults
Herbert Yajima
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA37647A1 publication Critical patent/MA37647A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

L'invention concerne de nouveaux procédés pour fabriquer et purifier des sels de composés de cyclopentapyrimidine hydroxylée, qui sont utiles en tant qu'inhibiteurs d'akt utilisés dans le traitement de maladies telles que le cancer, comprenant le sel monochlorhydrate de (s)-2-(4-chlorophényl)-1-(4-((5r,7r)-7-hydroxy-5-méthyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-4-yl)pipérazin-1-yl)-3-(isopropylamino)propan-1-one.
MA37647A 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci MA37647A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648535P 2012-05-17 2012-05-17
PCT/US2013/041695 WO2013173784A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Publications (1)

Publication Number Publication Date
MA37647A1 true MA37647A1 (fr) 2016-03-31

Family

ID=48534508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37647A MA37647A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Country Status (18)

Country Link
US (1) US9315471B2 (fr)
EP (1) EP2850200A1 (fr)
JP (1) JP6355625B2 (fr)
KR (1) KR102123131B1 (fr)
CN (1) CN104471070B (fr)
AU (1) AU2013262521B2 (fr)
BR (1) BR112014028573B1 (fr)
CA (1) CA2873661C (fr)
HK (1) HK1208500A1 (fr)
IL (1) IL235699B (fr)
MA (1) MA37647A1 (fr)
MX (1) MX354373B (fr)
MY (1) MY169029A (fr)
NZ (1) NZ702950A (fr)
RU (1) RU2642311C2 (fr)
SG (1) SG11201407591PA (fr)
WO (1) WO2013173784A1 (fr)
ZA (1) ZA201409226B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2861583T3 (pl) 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
ES2668477T3 (es) 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
US9290458B2 (en) 2012-05-17 2016-03-22 Genentech, Inc. Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof
CN105899492B (zh) * 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
JP6676043B2 (ja) 2014-09-26 2020-04-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト （シクロペンチル［ｄ］ピリミジン−４−イル）ピペラジン化合物を調製する方法
BR112019002007B1 (pt) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
US20220025424A1 (en) * 2016-08-16 2022-01-27 Imago Biosciences, Inc. Compositions and methods for producing stereoisomerically pure aminocyclopropanes
WO2019122421A1 (fr) * 2017-12-22 2019-06-27 Astrazeneca Ab Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase
US20230271958A1 (en) 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE
WO2023043869A1 (fr) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de citrate d'ipatasertib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408197A (pt) 1993-12-12 1997-08-26 Agrogene Ltd Método para proteger plantas contra doenças fúngicas
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
WO1999023242A1 (fr) * 1997-11-04 1999-05-14 Eli Lilly And Company Gene et proteine de cetoreductase de levure
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
DE10119274A1 (de) * 2001-04-20 2002-10-31 Juelich Enzyme Products Gmbh Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen
EP1636200A2 (fr) 2003-06-09 2006-03-22 Boehringer Ingelheim International GmbH Inhibiteurs du papillomavirus
PT1898903E (pt) * 2005-06-10 2013-06-28 Merck Sharp & Dohme Inibidores da atividade de akt
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR101586503B1 (ko) * 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
WO2011050016A1 (fr) 2009-10-23 2011-04-28 Eli Lilly And Company Inhibiteurs d'akt
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
ES2668477T3 (es) 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
PL2861583T3 (pl) 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
AU2014237198A1 (en) 2013-03-15 2015-11-05 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
BR112014028573B1 (pt) 2021-11-16
IL235699A0 (en) 2015-01-29
KR20150018579A (ko) 2015-02-23
MX354373B (es) 2018-02-28
MY169029A (en) 2019-02-04
IL235699B (en) 2018-12-31
CN104471070B (zh) 2018-09-25
JP6355625B2 (ja) 2018-07-11
SG11201407591PA (en) 2015-01-29
JP2015518715A (ja) 2015-07-06
CA2873661C (fr) 2020-07-21
RU2642311C2 (ru) 2018-01-24
HK1208500A1 (en) 2016-03-04
CA2873661A1 (fr) 2013-11-21
CN104471070A (zh) 2015-03-25
ZA201409226B (en) 2017-09-27
US20150099880A1 (en) 2015-04-09
AU2013262521B2 (en) 2017-03-02
NZ702950A (en) 2016-09-30
MX2014013855A (es) 2016-03-21
RU2014151014A (ru) 2016-07-10
AU2013262521A1 (en) 2015-01-22
WO2013173784A1 (fr) 2013-11-21
BR112014028573A2 (pt) 2018-04-24
KR102123131B1 (ko) 2020-06-15
US9315471B2 (en) 2016-04-19
EP2850200A1 (fr) 2015-03-25

Similar Documents

Publication Publication Date Title
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
MA37649A1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
WO2010147898A3 (fr) Inhibiteurs à petite molécule de la tyrosine kinase de la rate (syk)
PE20180050A1 (es) Heterociclos biciclicos como inhibidores de fgfr 4
MX368042B (es) COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA RELACIONADA CON ATAXIA TELANGIECTASIA MUTADA Y Rad3 (ATR).
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
IN2014KN02410A (fr)
IN2014KN00943A (fr)
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
EA201391528A1 (ru) Ингибиторы тирозинкиназы
EA201270480A1 (ru) Новые соединения
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MY196185A (en) Salts of a Pim Kinase Inhibitor
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA201692255A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
JP2011509306A5 (fr)
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
SG10201806450SA (en) PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS
MA39020A1 (fr) Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
MX2015005977A (es) Sal y formas polimorficas de (3r, 4s)-l-( (4-amino-5h-pirrolo [3,2-d] pirimidin-7-il) metil)-4 (metiltiometil) pirodin-3-ol(mtdia).
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam